Form D · Biotechnology
X2 Biosystems, Inc.
Seattle, WA · CIK 0001495809
Offering snapshot reported Apr 16, 2015 · SEC filing
- Reported sold
- $350K Offering amount: $350K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 2, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 16, 2015 | Initial | $350,000 | No comparison | 3 | SEC filing |
| Nov 20, 2014 | Amendment | $4,220,000 | $1,710,000vs Apr 18, 2014 | 41 | SEC filing |
| Apr 18, 2014 | Initial | $2,510,000 | No comparison | 17 | SEC filing |
| Dec 19, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jul 12, 2013 | Initial | $720,000 | No comparison | 8 | SEC filing |
| Jun 19, 2013 | Amendment | $3,273,021 | $1,157,040vs Feb 13, 2013 | 18 | SEC filing |
| Feb 13, 2013 | Amendment | $2,115,981 | $1,740,981vs Aug 17, 2012 | 18 | SEC filing |
| Aug 17, 2012 | Initial | $375,000 | No comparison | 2 | SEC filing |
| Sep 13, 2011 | Initial | $350,000 | No comparison | 5 | SEC filing |
| May 17, 2011 | Amendment | $1,970,000 | $865,000vs Jan 5, 2011 | 30 | SEC filing |
| Jan 5, 2011 | Amendment | $1,105,000 | $0vs Jan 4, 2011 | 12 | SEC filing |
| Jan 4, 2011 | Amendment | $1,105,000 | $905,000vs Jul 2, 2010 | 12 | SEC filing |
| Jul 2, 2010 | Initial | $200,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-238162
Source: Form D, filed Apr 16, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Able | Director, Executive |
| Christoph E. Mack | Director, Executive |
| Jim Mora | Executive |
| Peter Noone | Executive |
| John Ralston | Director, Executive |
| Robert G. Rosen | Director |
| Chris Siege | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1927 Post Alley Suite 200
Seattle, WA, 98101
Seattle, WA, 98101